Registration Number
0223U003427,
0118U000937
, R & D reports
Title
Clinical significance of inflammation markers and metabolic disorders in patients with NAFLD considering comorbidity
popup.stage_title
Head
Zhelezniakova Nataliia M., Доктор медичних наук
Registration Date
02-05-2023
Organization
Kharkiv National Medical University
popup.description2
Patients with an associated course of NAFLD and HC have changes in the lipid profile (increased total cholesterol and TG), increased levels of insulin and NOMA-IR, more often there are increased indicators of liver tests, which is considered a surrogate marker of inflammation in the liver tissue. A comprehensive evaluation of the indicated indicators is one of the criteria for diagnosing disorders of lipid and carbohydrate metabolism, and makes it necessary to carry out primary and secondary prevention measures of fibrotic changes in the liver and the progression of cardiovascular pathology, in particular, arterial hypertension. The presence of GC in patients with NAFLD worsens the state of portal blood flow, which is manifested by an increase in the diameter of the portal vein and a decrease in the maximum and minimum blood flow velocity in it, as well as an increase in the diameter of the common hepatic artery and the resistance index. Conducting an in-depth ultrasound examination in patients with NAFLD and HC, namely the determination of portal blood flow indicators, helps to detect pathological changes at an early stage, which in turn allows early implementation of preventive and therapeutic measures.
Product Description
popup.authors
Aleksandrova Tetiana M.
Babak Oleg Ya.
Vizir Maryna O.
Goptsij Olena V.
Zajchenko Ol'ga Ye.
Karpenko Iryna I.
Klimenko Mykola I.
Laphyna Kateryna A.
Molodan Volodymyr I.
Ovcharenko Lyudmyla I.
Panchenko Galyna Yu.
Prosolenko Konstanstin O.
Rozhdestvenska Alesia O.
Tverezovska Iryna I.
Frolovа-Romaniuk Elina Yu.
Shalimova Anna S.
popup.nrat_date
2023-05-02
